-
Thiothixene: From D2 Blockade to Precision Research
2026-09-15
Thiothixene is a typical antipsychotic agent with applications spanning dopamine receptor pharmacology and macrophage biology. This evidence-focused guide connects its efferocytosis activity with emerging schizophrenia target discovery while clarifying assay design, translational relevance, and scientific limitations.
-
Platelet Extravasation and Tumor Growth Control
2026-09-15
The reference study defines platelet transendothelial migration into tumors as a regulated process controlled by CXCL12/CXCR4 signaling, FAK, PECAM-1, and the CLEC-2/podoplanin vascular pathway. Its most important conceptual advance is separating platelet trafficking from platelet effector activity, showing that distinct granule-release programs can either promote tumor growth or preserve vascular integrity.
-
Naloxone Hydrochloride: From Blockade to Translation
2026-09-14
Naloxone hydrochloride is more than a standard opioid receptor antagonist: it can serve as a mechanistic control across receptor signaling, neural stem cell, immune, and behavioral workflows. This translational guide connects assay design, product quality, and cross-domain drug-discovery strategy without confusing research evidence with clinical conclusions.
-
Gamithromycin PK/PD in Bovine Respiratory Disease
2026-09-14
This prospective clinical study linked gamithromycin exposure with treatment outcome in cattle with naturally occurring bovine respiratory disease, emphasizing pulmonary epithelial lining fluid as a pharmacologically relevant effect compartment. Its modeling strategy shows why site-of-infection PK/PD indices can provide more useful response predictions than plasma measurements alone.
-
ALDOB K87 Lactylation in Pulmonary Hypertension
2026-09-13
The 2026 reference study identifies ALDOB K87 lactylation as a mechanistic link between hypoxia-associated glycolytic rewiring, mitochondrial fission, and pulmonary vascular remodeling. Its lactate–ALDOB–DRP1 axis provides a framework for studying how nonhistone post-translational modifications regulate pulmonary artery smooth muscle cell behavior.
-
Dabigatran: Mechanism, Evidence, and Research Use
2026-09-12
Dabigatran is a reversible direct thrombin inhibitor that blocks both free and fibrin-bound thrombin. As Pradaxa, it has established clinical roles in stroke prevention in atrial fibrillation and venous thrombosis treatment, while research-grade material supports thrombin inhibition assays and coagulation function tests.
-
WNT-Driven Bile Duct Proliferation After Obstruction
2026-09-12
Calder and colleagues show that obstruction-induced proliferation in the mouse extrahepatic bile duct is linked to locally activated, β-catenin-dependent WNT signaling. By combining bile duct ligation with mouse and human biliary organoids, explants, pharmacologic pathway modulation, and transcriptomic analysis, the study identifies cholangiocyte-derived WNT ligands, including WNT7B, as contributors to the injury response.
-
Betulinic Acid, ERK, and Cyclophosphamide Liver Injury
2026-09-11
This 2025 mouse study identifies ERK-linked mitochondrial apoptosis as an important component of cyclophosphamide-induced oxidative liver damage and shows that betulinic acid attenuates this injury. Its combined use of antioxidant, mitochondrial, apoptotic, and pharmacological pathway readouts offers a useful framework for evaluating hepatoprotective mechanisms, while remaining preclinical.
-
Doxorubicin Workflows for Cardiotoxicity Research
2026-09-11
Build reproducible Doxorubicin assays that connect tumor-cell killing with oxidative stress, autophagy, apoptosis, and cardiac safety readouts. This workflow translates the aucubin–NRF2–HIPK2 findings into practical paired cancer and cardiotoxicity experiments.
-
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-09-10
Borchert et al. linked homologous recombination repair defects, including BAP1-associated BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their combined cell-line and clinical gene-expression strategy identifies a rationale for PARP inhibition, particularly with cisplatin, while also clarifying why these findings remain hypothesis-generating rather than clinically validated.
-
In Vitro Drug Response Metrics in Cancer Research
2026-09-10
Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability are not interchangeable measures of anticancer drug response. By separating growth inhibition from cell killing and considering their different timing, the study offers a more precise framework for designing, analyzing, and reporting in vitro cancer research experiments.
-
Moxidectin: From Dewormer to Fungal Sensitizer
2026-09-09
A translational perspective on how Moxidectin moves from established parasitic worm control into mechanism-driven polyene combination research against Candida albicans.
-
Caco-2 Permeability of Ziprasidone Nanocrystals
2026-09-09
The reference study investigated whether nanocrystal engineering could improve the in vitro transport of ziprasidone hydrochloride monohydrate across Caco-2 cell monolayers. PVP-stabilized nanocrystals increased permeability 2.3-fold versus coarse powder without reducing measured cell viability, supporting a formulation-based strategy for overcoming dissolution-limited absorption.
-
BAPTA Calcium Chelator Workflow for Apoptosis
2026-09-08
BAPTA enables a practical test of whether calcium elevation is causally involved in toxicant-induced apoptosis rather than merely correlated with it. This workflow translates IP3R/Ca2+/STAT3 findings into controlled cell assays, dose planning, and troubleshooting for calcium signaling modulation.
-
CCK8 Workflow for Lung Cancer Cell Assays
2026-09-08
Build a reproducible cck8 workflow for measuring lung cancer cell proliferation, viability, and treatment response. This guide connects WST-8 assay design with the CCT3–PI3K/AKT–EMT findings reported in the reference study, while emphasizing controls, orthogonal validation, and practical troubleshooting.